Remove Drug Delivery Remove Filler Remove In-Vivo
article thumbnail

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. About TLC599.

Trials 40